Disclaimer to the Online Edition
This Manual has been designed for use in the NICU at London Health Sciences Centre (LHSC), London, Ontario, Canada, and represents clinical practice at this institution. The information contained within the Manual may not be applicable to other centres. If users of this Manual are not familiar with a drug, it is recommended that the official monograph be consulted before it is prescribed and administered. Any user of this information is advised that the contributors, Editor and LHSC are not responsible for any errors or omissions, and / or any consequences arising from the use of the information in this Manual.
nirsevimab (Beyfortus™)
Indication
- A monoclonal antibody used for the prevention of serious lower respiratory tract disease caused by respiratory syncytial virus (RSV) in infants born in or approaching their first RSV season and children up to 24 months of age who are at high risk for RSV
- Monoclonal antibodies provide passive immunity, and immediate protection by supplying the body with ready-made antibodies.
Dosage Guidelines
- Weight less than 5 kg: 50 mg as a single dose
- Weight 5 kg or greater: 100 mg as a single dose
Administration
- IM (anterolateral aspect of the thigh preferred)
Adverse Effects
- Skin rash, injection site reaction
- Hypersensitivity reaction (rare)
Comments
- In Southwestern Ontario the RSV season generally extends from November to April
- Observe injection site for induration and swelling
- Caution with IM injections in patients with low platelet counts, coagulation disorders and patients receiving anticoagulants
- Nirsevimab administration does not appear to alter the response to any vaccines. Therefore, routine childhood immunization schedules do NOT need to be altered
Supplied As
- 50 mg/0.5 mL and 100 mg/1 mL pre-filled syringes
References
Lexidrug Pediatric and Neonatal, Beyfortus™ Product Monograph